Rapidly progressive glomerulonephritis (RPGN) is often associated with the presence of autoantibodies. Included in this group are the glomerulonephritides associated with anti-GBM antibody (Goodpasture's syndrome). IgA mesangial deposition (the renal component of Henoch-Schönlein purpura), lupus erythematosus, cryoglobulinemia and the antineutrophil cytoplasmic antibody (ANCA)-associated pauci-immune group. In each of these cases, apheresis may provide a therapeutically useful option. Apheresis has also been found useful in certain types of antibody-mediated transplant rejection and in lowering the levels of preformed cytotoxic antibodies which may preclude transplantation. Finally, there are renal diseases in which the immune component is less clearly involved with pathogenesis but for which apheresis may offer a clear benefit, such as in the renal failure associated with 'cast nephropathy' (multiple myeloma) or the recurrence of FSGS (focal segmental glomerulosclerosis) in transplanted kidneys. It is the purpose of this paper to review the evidence supporting the use of apheresis in immune-related diseases.